1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,420 | 1,540 | 11:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:14 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I MULTIPLE DOSE EXPANSION STUDY OF LAE102 FOR THE TREATMENT OF OBESITY | 1 | HKEx | ||
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 15.12. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) IN HR+/HER2- ... | 2 | HKEx | ||
| 12.12. | LAEKNA-B (02105): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | 1 | HKEx | ||
| 12.12. | LAEKNA-B (02105): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 12.12. | LAEKNA-B (02105): CHANGE OF THE COMPOSITION OF THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | 1 | HKEx | ||
| 12.11. | LAEKNA-B (02105): INSIDE INFORMATION EXCLUSIVE LICENSE AGREEMENT WITH QILU PHARMA FOR LAE002 (AFURESERTIB) IN THE CHINA REGION | 1 | HKEx | ||
| 29.09. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT POSITIVE PRELIMINARY RESULTS FROM THE PHASE I MAD STUDY LAE102 DEMONSTRATED ENCOURAGING TREND TOWARDS LEAN BODY ... | 2 | HKEx | ||
| 17.09. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 17.09. | LAEKNA-B (02105): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 10.09. | LAEKNA-B (02105): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 21.08. | LAEKNA-B (02105): INTERIM REPORT 2025 | - | HKEx | ||
| 13.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 31.07. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE103 WAS OBTAINED FROM THE U.S. FOOD AND DRUG ADMINISTRATION | 1 | HKEx | ||
| 29.07. | LAEKNA-B (02105): DATE OF BOARD MEETING | - | HKEx | ||
| 30.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE103 TO THE U.S. FOOD AND DRUG ADMINISTRATION | 2 | HKEx |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,58 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| RELAY THERAPEUTICS | 8,400 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| IMMUNEERING | 5,650 | 0,00 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,580 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | 0,00 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
LAEKNA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,490 Euro und damit -9,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAEKNA INC finden Sie auf Wallstreet Online.